ICW Investment Advisors LLC Has $2.24 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

ICW Investment Advisors LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,593 shares of the medical research company’s stock after buying an additional 110 shares during the quarter. ICW Investment Advisors LLC’s holdings in Amgen were worth $2,240,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in AMGN. Swedbank AB raised its stake in shares of Amgen by 1.1% in the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after buying an additional 5,751 shares in the last quarter. Icon Wealth Advisors LLC raised its stake in shares of Amgen by 3,955.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock valued at $56,000 after buying an additional 169,748 shares in the last quarter. Great Valley Advisor Group Inc. raised its stake in shares of Amgen by 130.4% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 17,908 shares of the medical research company’s stock valued at $5,770,000 after buying an additional 10,136 shares in the last quarter. Truepoint Inc. bought a new stake in shares of Amgen in the 3rd quarter worth about $207,000. Finally, WESPAC Advisors LLC grew its holdings in shares of Amgen by 30.8% in the 3rd quarter. WESPAC Advisors LLC now owns 4,181 shares of the medical research company’s stock worth $1,347,000 after purchasing an additional 985 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $316.04 on Monday. The company has a market capitalization of $169.78 billion, a price-to-earnings ratio of 41.86, a P/E/G ratio of 2.63 and a beta of 0.53. The firm’s 50 day simple moving average is $297.24 and its 200 day simple moving average is $298.57. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, sell-side analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.01%. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Analyst Ratings Changes

Several research firms have recently weighed in on AMGN. UBS Group reaffirmed a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Redburn Partners lowered their target price on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $314.04.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the transaction, the executive vice president now directly owns 44,186 shares in the company, valued at approximately $13,025,590.94. The trade was a 16.56 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.